For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission

Editas Medicine lays off 65% of staff and shelves lead gene-editing program

December 13, 2024 Check out STAT+

Sponsored By

Sandy Huffaker for STAT STAT+ | Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? For more than 30 years, Ionis developed medicines in partnership with Big Pharma. This time, it is standing alone By Jonathan Wosen and Matthew Herper STAT+ | For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to kick." By Angus Chen STAT+ | Editas Medicine lays off 65% of staff and shelves lead gene-editing program Despite promising data for its experimental CRISPR treatment, Editas announced a major shift in direction. By Jason Mast Bill Sikes/AP STAT+ | South African regulator decides Vertex provides sufficient access to CF drugs, angering activists "Patients will die as a result of this decision," said Gayle Pledger of the Right to Breathe advocacy campaign. By Ed Silverman HHMI's move to diversify funding sparks debate about 'biomedical elite' HHMI Investigator Program to expand beyond a handful of elite institutions, diversify research funding. 'Talent is everywhere, but opportunities are not.' By Anil Oza STAT+ | Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds The report found that the U.S. National Institutes of Health and the Bill & Melinda Gates Foundation contributed 53% of all R&D TB funds. By Ed Silverman Cynthia Goldsmith/CDC CDC finds no evidence of bird flu virus in California toddler Public health labs in California failed to confirm a positive result. Sample sent to the CDC, which Thursday said it was negative for "all flu targets." By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser